Patent Certification. To the extent required by law or permitted by law, the Parties shall use Commercially Reasonable Efforts to maintain with the applicable Regulatory Authorities during the Term correct and complete listings of applicable Patent Rights for the Licensed Product being commercialized.
Patent Certification. To the extent required by law or permitted by law, the Parties shall use reasonable efforts to maintain with the applicable regulatory authorities during the Term correct and complete listings of applicable Patents for Alnylam Products or Tekmira Products, as the case may be, being Commercialized, including but not limited to all so-called “Orange Book” listings required under the Xxxxx-Xxxxxx Act.
Patent Certification. The Parties agree that as of the Effective Date there are several patents listed in the Orange Book for the Product for which a Paragraph IV certification is expected to be filed and may have to be litigated.
Patent Certification. To the extent required by law or permitted by law, the Parties shall use Commercially Reasonable Efforts to maintain with the applicable Regulatory Authorities during the Term correct and complete listings of applicable Patent Rights for the Covered Product being commercialized. Confidential and Proprietary CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.
Patent Certification. Chimerix shall inform Merck of any certification regarding any Chimerix Patent Rights it has received pursuant to either 21 U.S.C. §§355(b)(2)(A)(iv) or (j)(2)(A)(vii)(IV) or its successor provisions, or any similar provisions in a country in the Territory, and Chimerix shall provide Merck with a copy of such certification within five (5) days of receipt. Chimerix’s and Merck’s rights with respect to the initiation and prosecution of any legal action as a result of such certification or any recovery obtained as a result of such legal action shall be as defined in Sections 7.5.1 through 7.5.6 hereof; provided, however, that Merck may exercise its first right to initiate and prosecute any action (in accordance with Section 7.5.2) and shall inform Chimerix of such decision within ten (10) days of Chimerix’s receipt of the certification, after which time Chimerix shall have the right to initiate and prosecute such action; and provided, further, that if such certification pertains to any of the Chimerix/UC Patent Rights, then the foregoing five (5)-day and ten (10)-day notification periods shall be reduced to two (2) days and five (5) days, respectively, in order to permit Chimerix to comply with its notification obligations under the UC License. Regardless of which Party has the right to initiate and prosecute such action, both Parties shall, as soon as practicable after receiving notice of such certification, convene and consult with each other regarding the appropriate course of conduct for such action. The non-initiating Party shall have the right to be kept fully informed and participate in decisions regarding the appropriate course of conduct for such action, and the right to join and participate in such action.
Patent Certification. Upon contract expiration and completion of all work authorized under this contract, the Contractor shall complete and execute the Attachment (D) “Patent Certification” clearance form and forward it to the Contractual Representative. Failure to do so may result in the withholding of final payment or a portion thereof.
Patent Certification. To the extent required by law or permitted by law, the Parties shall use Commercially Reasonable Efforts to maintain with the applicable Regulatory Authorities during the Agreement Term correct and complete listings of applicable Patent Rights for Ophthalmic Products being commercialized, including all so called "Orange Book" listings required under the Hatch-Waxman Act.
Patent Certification. To the extent required by law or permitted by law, the Parties shall use Commercially Reasonable Efforts to maintain with the applicable Regulatory Authorities during the Agreement Term correct and complete listings of applicable Patent Rights for the each Selected RNAi Therapeutic being Commercialized, including all so-called "Orange Book" listings required under the Xxxxx-Xxxxxx Act.
Patent Certification. Invention Name: Xxx Xxxx (R) Ban Bu Xx Xxx and its pharmaceuticals usage Inventor: Xxxx Xxxx Long; Xxx Xxx Patent Number: ZL02829397.5 Application date of the patent: August 8, 2002 The holder of the patent: Tan Wen Authorization Date: December 26, 2007 The invention has been examined by our department according to P.R.C. patent law and our department decides to give the patent to the invention and award the certification to the invention and our department will registered it on the patent registration book. The patent will be put into effect after the authorization notice is published. The patent period of the patent is 20 years. The patent period will be calculated from the application day. The holder of the patent must pay the annual fee according to the patent law and its detail description. The annual fee will be paid by the fore-month of each August 8. If the holder of the patent does not pay the annual fee, the patent will be ceased after the due date. Seal of P.R.C. Intelligence Property Department December 26, 2007 Chairman: /s/ Tian Li Pu Attachment Two
Patent Certification. To the extent required by law or permitted by law, the Parties shall use Commercially Reasonable Efforts to maintain with the applicable Regulatory Authorities during the Agreement Term correct and complete listings of applicable Patent Rights for RNAi Therapeutic Products and [**] Products being commercialized, including all so called "Orange Book" listings required under the Hatch-Waxman Act. The provisions of this Section 11.10 shall axxxx xx Xxxxnt Rights Covering or claiming a MERCK Development Product to the extent such Patent Rights are included in ALNYLAM Technology licensed to MERCK with respect to such MERCK Development Product pursuant to Section 7.1 and to a [**] Product to the extent such Patent Rights are included in MERCK Technology licensed to ALNYLAM with respect to such [**] Product pursuant to Section 7.1. 80
